
Cyclacel Pharmaceuticals Investor Relations Material
Latest events

Q2 2024
Cyclacel Pharmaceuticals

Q1 2025
15 May, 2025

Q4 2024
2 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cyclacel Pharmaceuticals Inc
Access all reports
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company's research and development efforts target the regulation of the cell cycle, aiming to treat cancers and other serious diseases that result from abnormal cell division. Cyclacel's pipeline includes small-molecule drugs designed to inhibit specific enzymes and proteins involved in cancer cell growth and survival. The company's therapeutic candidates are being developed for a range of oncology applications, with the goal of addressing unmet medical needs in cancer treatment. The company is headquartered in Berkeley Heights, New Jersey, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
CYCC
Country
🇺🇸 United States